Purple Biotech(NASDAQ) PPBT

Current Price$1.35

Market Cap$2.35M

Since IPO (2015)-100%

5 Year-100%

1 Year-94%

1 Month-15%

Purple Biotech last closing stock price
Metric	Price	Date
Last close	USD 1.45	2026-07-20

Purple Biotech stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-4.61%	USD 1.52	2026-07-13
1 month	-14.71%	USD 1.70	2026-06-18
3 month	-69.26%	USD 4.72	2026-04-21
Year to date	-77.95%	USD 6.58	2025-12-31
1 year	-94.42%	USD 26.00	2025-07-18
3 year	-99.41%	USD 244.00	2023-07-21
5 year	-99.85%	USD 998.00	2021-07-21
Since inception	-99.98%	USD 5,980.00	2015-11-23

Purple Biotech Financials at a Glance

Market Cap

$2.35M

Revenue (TTM)

$0.00

Net Income (TTM)

-$26.17M

EPS (TTM)

-$32.52

P/E Ratio

-0.04

Dividend

$0.00

Beta (Volatility)

0.54 (Low)

Dividend

$0.00

Beta (Volatility)

0.54 (Low)

Price

$1.35

Volume

18,088.268

Open

$1.46

Price

$1.35

Volume

18,088.268

Open

$1.46

Previous Close

$1.45

Daily Range

$1.35 - $1.46

52-Week Range

$1.35 - $29.00

Estimated Earnings Date

Aug 5, 2026

Dividend

$0.00

Beta (Volatility)

0.54 (Low)

Price

$1.35

Volume

18,088.268

Open

$1.46

Previous Close

$1.45

Daily Range

$1.35 - $1.46

52-Week Range

$1.35 - $29.00

Estimated Earnings Date

Aug 5, 2026

PPBT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Purple Biotech

Purple Biotech Ltd. is a clinical-stage biotechnology firm based in Rehovot, Israel, focused on developing innovative treatments for cancer patients. The company aims to address tumor immune evasion and drug resistance through its advanced oncology pipeline.

Products and Services

CM24: Monoclonal antibody targeting CEACAM1, in Phase 1b/2 trials
NT219: Small molecule compound targeting IRS1/2 and STAT pathways, in Phase 1/2 studies
Combination therapies for non-small cell lung cancer and pancreatic cancer

Growth Outlook

Strong pipeline with two promising oncology assets in clinical trials
Potential market expansion in the U.S. cancer treatment sector
Focus on overcoming drug resistance may attract strategic partnerships

Financial Highlights

Recent quarterly net income of -$85,766, reflecting ongoing R&D investments
Cash and cash equivalents of $5,567,000 as of March 31, 2026
Trailing twelve months (TTM) cash flow from operations shows significant investment in growth

Purple Biotech Ltd. is positioned in the biotechnology sector with a focus on oncology, which is a rapidly growing market. The company's innovative approach to treating cancer through its clinical trials may provide significant opportunities for future growth. With a strong emphasis on research and development, Purple Biotech aims to address critical challenges in cancer treatment, potentially leading to valuable partnerships and advancements in patient care. The financial data indicates a commitment to investing in its pipeline, which may appeal to investors looking for long-term growth in the healthcare sector.

AI Generated • Jun 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Gil Efron, MBA, CPA

Website

www.purple-biotech.com

Headquarters

Rehovot, TA 7670104, IL

PPBT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-123.47%

Return on Capital

-275.74%

Return on Assets

-178.79%

Earnings Yield

-25.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.35M

Shares Outstanding

1.62M

Volume

18.09K

Avg. Volume

309.04K

Financials (TTM)

Gross Profit

-$53.33K

Operating Income

-$7.84M

EBITDA

-$5.21M

Operating Cash Flow

-$6.80M

Capital Expenditure

-$2.01K

Free Cash Flow

-$6.80M

Cash & ST Invst.

$6.43M

Total Debt

$184.00K

Purple Biotech Performance Analysis

Purple Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Purple Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

Purple Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -233.56	13.0%
2023	2023-12-31	USD -161.08	-31.0%
2024	2024-12-31	USD -28.13	-82.5%
2025	2025-12-31	USD -55.40	96.9%

Purple Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-122.2%
Q3	2025-09-30	-900.0%
Q4	2025-12-31	-24575.0%
Q1	2026-03-31	99.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$2.35M

N/A

Market Cap/Employee

$234.65K

N/A

Employees

N/A

Net Income

-$86.00K

+81.0%

EBITDA

$7.00K

+101.9%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$6.43M

-9.3%

Total Debt

$184.00K

+34.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$184.00K

-32.8%

Return on Assets

-1.79%

N/A

Return on Invested Capital

-3.08%

N/A

Free Cash Flow

-$3.12M

-57.8%

Operating Cash Flow

-$3.12M

-57.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CDTCDT Equity Inc.

CDTCDT Equity Inc.$3.75+5.19%

DRMADermata Therapeutics, Inc.

DRMADermata Therapeutics, Inc.$1.25-1.57%

FOXOFOXO Technologies Inc.

FOXOFOXO Technologies Inc.$0.06+57.50%

XAGELongevity Health Holdings Inc.

XAGELongevity Health Holdings Inc.$0.23-6.25%

REVBRevelation Biosciences, Inc.

REVBRevelation Biosciences, Inc.$1.15-0.86%

MSPRMSP Recovery, Inc.

MSPRMSP Recovery, Inc.$0.01-52.38%

VINCVincerx Pharma, Inc.

VINCVincerx Pharma, Inc.$0.01-15.89%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$7.59+0.10%

NOKNokia

NOKNokia$10.62+0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$15.19+0.00%

HLHecla Mining

HLHecla Mining$15.15+0.06%

UTZUtz Brands

UTZUtz Brands$14.07+0.89%

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$34.72+0.23%

FFord Motor Company

FFord Motor Company$14.27+0.02%

Questions About PPBT

What is the current price of Purple Biotech?

Purple Biotech is trading at $1.35 per share.

What is the 52-week range for Purple Biotech?

Over the past 52 weeks, Purple Biotech has traded between $1.35 and $29.00.

How much debt does Purple Biotech have?

As of the most recent reporting period, Purple Biotech reported total debt of $184.00K.

How much cash does Purple Biotech have on hand?

Purple Biotech reported $5.57M in cash and cash equivalents in its most recent financial results.

What is Purple Biotech’s dividend yield?

Purple Biotech does not currently have a dividend yield.

Purple Biotech(NASDAQ) PPBT

Purple Biotech Financials at a Glance

PPBT News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Purple Biotech

PPBT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Purple Biotech Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PPBT

What is the current price of Purple Biotech?

What is the 52-week range for Purple Biotech?

How much debt does Purple Biotech have?

How much cash does Purple Biotech have on hand?

What is Purple Biotech’s dividend yield?

Premium Investing Services